UNSPSC 85315608: Diagnosis of cerebral amyloid antipathy

This classification denotes the group of activities that yields a diagnosis of Cerebral amyloid angiopathy. Cerebral amyloid antipathy is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as a four digit category under code I68.0

UNSPSC 85315608 Diagnosis of cerebral amyloid antipathy is a Commodity code that represents specialized neurological diagnostic services, yet the recent state and local opportunities on file show no direct alignment with this code's nominal scope. The three most recent solicitations tagged to this code involve diagnostic imaging Picture Archiving and Communication System (PACS) implementation, special education contracted services across multiple disciplines, and temporary health professional staffing in ancillary clinical categories—none of which address cerebral amyloid antipathy diagnosis specifically. The PACS opportunity does encompass enterprise-grade imaging infrastructure that could support advanced neuroimaging, but the solicitations do not frame the work as targeting amyloid-related pathology or specialized neurodegenerative disease protocols.

The geographic distribution of these opportunities spans California (San Mateo County Medical Center and Santa Clara County Health System) and Texas (Birdville Independent School District), though only the two health system opportunities approach the code's clinical scope. San Mateo Medical Center posted an RFP on October 7, 2026, for Diagnostic Imaging PACS with proposals due October 21, 2026, seeking enterprise radiology, cardiology, and dental imaging capability with EPIC integration and 9–12 month implementation. Santa Clara County Health System posted an RFQ on July 7, 2026, due October 7, 2026, establishing a qualified vendor pool for temporary health professional staffing across 13 ancillary clinical categories including Diagnostic Imaging/Radiology and Therapy Services. The code shows minimal relevant recent activity aligned with cerebral amyloid antipathy diagnosis; state and local procurement under this code does not currently reflect demand for specialized neurological diagnostic services or amyloid-specific diagnostic protocols.